JMP Securities analyst Jason Butler raised his price target on Esperion Therapeutics to $60 from $41 after the FDA confirmed that the company can pursue approval for bempedoic acid for an LDL-C lowering indication, which he believes supports NDA submission in 1H19 and a potential launch in 2020 and addresses a key investor concern. The analyst, who moved up his launch assumption and increased the probability of success for the drug to 75% from 67%, keeps an Outperform rating on Esperion shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here